IP Library › Granted Patent US 9,066,697
Granted Patent B2
US 9,066,697 · App. 13/283,562 · Granted Jun 30, 2015

Analyte monitoring device and methods of use

Inventors: Thomas Peyser (Menlo Park, CA); Adam Heller (Austin, TX)
Assignee: Abbott Diabetes Care Inc.
A61B5/14865A61B5/0031A61B5/14532A61B5/14546A61B5/4839A61B5/7445
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,066,697
App. No.
13/283,562
Granted
Jun 30, 2015
Kind
B2
Abstract

An analyte monitor including a sensor, a sensor control unit, and a display unit is disclosed. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.

Claims (59)

1. A device, comprising:

an implantable sensor configured to continuously measure in vivo signals associated with an analyte concentration; and

a membrane located over the sensor;

wherein the implantable sensor is configured to generate signals associated with the analyte concentration having a level of accuracy corresponding to a mean absolute relative difference, wherein the level of accuracy increases on subsequent days during a sensor session of at least 3 days, wherein one or more reference measurements associated with a calculation of the mean absolute relative difference are determined by analysis of blood.

2. The device of claim 1 , wherein the membrane comprises an enzyme configured to react with an analyte.

3. The device of claim 1 , wherein the membrane comprises a polyurethane portion.

4. The device of claim 1 , wherein the membrane comprises a copolymer comprising a polycarbonate segment.

5. A device, comprising:

an implantable sensor configured to continuously measure in vivo signals associated with an analyte concentration; and

a membrane located over the sensor;

wherein, over a sensor session of at least 3 days, the implantable sensor is configured to generate signals associated with the analyte concentration:

having a level of accuracy corresponding to a first mean absolute relative difference value during a first time period, wherein one or more reference measurements associated with a calculation of the first mean absolute relative difference value are determined by analysis of blood; and

having a level of accuracy corresponding to a second mean absolute relative difference value at analyte concentrations during a second time period, wherein one or more reference measurements associated with a calculation of the second mean absolute relative difference value are determined by analysis of blood;

wherein the first time period precedes the second time period, and further, wherein the first mean absolute relative difference value is greater than the second mean absolute relative difference value.

6. The device of claim 5 , wherein the first mean absolute relative difference value is less than or about equal to the second mean absolute relative difference value.

7. The device of claim 5 , wherein the membrane comprises an enzyme configured to react with an analyte.

8. The device of claim 5 , wherein the membrane comprises a polyurethane portion.

9. The device of claim 5 , wherein the membrane comprises a copolymer comprising a polycarbonate segment.

10. A system, comprising:

an implantable sensor comprising a sensing region configured to continuously produce in vivo sensor data associated with an analyte concentration, wherein the sensor further comprises a membrane located over the sensing region;

a processor configured to process continuous sensor data; and

a user interface configured to display information associated with the continuous sensor data;

wherein the sensor is configured to produce sensor data associated with the analyte concentration having a level of accuracy corresponding to a mean absolute relative difference, wherein the level of accuracy increases on subsequent days during a sensor session of at least 3 days, wherein one or more reference measurements associated with a calculation of the mean absolute relative difference are determined by analysis of blood.

11. The system of claim 10 , wherein the membrane comprises an enzyme configured to react with an analyte.

12. The system of claim 10 , wherein the membrane comprises a polyurethane portion.

13. The system of claim 10 , wherein the membrane comprises a copolymer comprising a polycarbonate segment.

14. A system, comprising:

an implantable sensor comprising a sensing region configured to continuously produce in vivo a signal associated with an analyte concentration, wherein the sensor further comprises a membrane located over the sensor;

a processor configured to process continuous sensor data; and

a user interface configured to display information associated with the continuous sensor data;

wherein, over a sensor session of at least 3 days, the implantable sensor is configured to generate signals associated with the analyte concentration:

having a level of accuracy corresponding to a first mean absolute relative difference value during a first time period, wherein one or more reference measurements associated with a calculation of the first mean absolute relative difference value are determined by analysis of blood; and

having a level of accuracy corresponding to a second mean absolute relative difference value during a second time period, wherein one or more reference measurements associated with a calculation of the second mean absolute relative difference value are determined by analysis of blood;

wherein the first time period precedes the second time period, and further, wherein the first mean absolute relative difference value is greater than the second mean absolute relative difference value.

15. The system of claim 14 , wherein the first mean absolute relative difference value is less than or about equal to the second mean absolute relative difference value.

16. The system of claim 14 , wherein the membrane comprises an enzyme configured to react with an analyte.

17. The system of claim 14 , wherein the membrane comprises a polyurethane portion.

18. The system of claim 14 , wherein the membrane comprises a copolymer comprising a polycarbonate segment.

19. A device, comprising:

an implantable sensor configured to continuously measure signals associated with an analyte concentration; and

a membrane located over the sensor, wherein the membrane comprises a polyurethane portion;

wherein the implantable sensor is configured to generate signals associated with the analyte concentration having a level of accuracy corresponding to a mean absolute relative difference, wherein the level of accuracy increases on subsequent days during a sensor session of at least 3 days, wherein one or more reference measurements associated with a calculation of the mean absolute relative difference are determined by analysis of blood.

20. The device of claim 19 , wherein the sensor session is at least 5 days.

21. The device of claim 19 , wherein the sensor session is at least 6 days.

22. The device of claim 19 , wherein the sensor session is at least 7 days.

23. The device of claim 19 , wherein the sensor session is at least 10 days.

24. The device of claim 19 , wherein the membrane comprises an enzyme configured to react with an analyte.

25. A system, comprising:

a sensor comprising:

a sensing region configured to continuously produce sensor data associated with an analyte concentration; and

a membrane located over the sensing region, wherein the membrane comprises a polyurethane portion;

a processor configured to process continuous sensor data; and

a user interface configured to display information associated with the continuous sensor data;

wherein the sensor is configured to produce sensor data associated with the analyte concentration having a level of accuracy corresponding to a mean absolute relative difference, wherein the level of accuracy increases on subsequent days during a sensor session of at least 3 days, wherein one or more reference measurements associated with a calculation of the mean absolute relative difference are determined by analysis of blood.

26. The system of claim 25 , wherein the sensor session is at least 5 days.

27. The system of claim 25 , wherein the sensor session is at least 6 days.

28. The system of claim 25 , wherein the sensor session is at least 7 days.

29. The system of claim 25 , wherein the sensor session is at least 10 days.

30. The system of claim 25 , wherein the membrane comprises an enzyme configured to react with an analyte.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2014
From: PEYSER, THOMAS A.; HELLER, ADAM
To: ABBOTT DIABETES CARE INC.
Reel/Frame 033915/0839 →
Continuity (5)
Continuation 11265787 · Nov 1, 2005
Continuation In Part 10420057 · Apr 18, 2003
Continuation 09667199 · Sep 21, 2000
Continuation 09070677 · Apr 30, 1998
Related Publication 20120108929A1 · May 3, 2012